The oldest user fee program at the US Food and Drug Administration could reach regulatory science research parity with its younger siblings after the next round of negotiations.
PDUFA VIII negotiations may not begin until 2025, but Center for Drug Evaluation and Research Director Patrizia Cavazzoni already envisions potentially proposing a prescription drug user fee
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?